Main investment projects:
Hangzhou Zhengxiang, Nanjing Aimeifei, Nanjing Weili Zhibo, Hangzhou Suizhen, Shanghai Shangke, Hangkang Pharmaceutical, Shanghai Hengxin, Changfeng Pharmaceutical, Shanghai Bowei Biology, Okoda Pharmaceutical, Paige Pharmaceutical, Taimei Medical, etc.
Dr. Chen is now the executive partner and founding partner of Ennovation Ventures. He has nearly 20 years of experience in the pharmaceutical and investment management industry. He has successively held the following positions:
- Partner, Nanjing Kaiyuan Venture Capital Partnership Co., Ltd;
- Biopharmaceutical partner, Suzhou Kaifeng Zhengde Investment Management Co., Ltd;
- Representative of China, Debug Pharmaceutical Group, Switzerland. Be responsible for finding original new drug projects that meet the needs of the Group nationwide, initial evaluation, internal and external communication, participation in due diligence, business negotiation and all businesses related to China;
- Head of R&D Department, Shanghai Target Drug Co., Ltd. Responsible for the management and operation of all drug R&D projects of the company (including drug discovery, preclinical development and clinical development), the application and management of scientific research funds, and the writing, submission and defense of new drug application materials.
- Bachelor of Science, Pharmacy, School of Pharmacy, Shanghai Second Military Medical University
- Master of Science, Molecular Biology and Cell Biology, Chinese Academy of Sciences, Shanghai Institute of Life Sciences
- MBA, Shanghai Jiaotong University - Kedge Business School, France
‐ Doctor of Medicine, Pharmacology, Shanghai Institute of Pharmaceutical Industry